Oruka Therapeutics, Inc. (ORKA) - Total Liabilities
Based on the latest financial reports, Oruka Therapeutics, Inc. (ORKA) has total liabilities worth $24.84 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Oruka Therapeutics, Inc. strategic investment ratio to see how much of total assets are deployed in long-term investments.
Oruka Therapeutics, Inc. - Total Liabilities Trend (2005–2025)
This chart illustrates how Oruka Therapeutics, Inc.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see ORKA total asset value.
Oruka Therapeutics, Inc. Competitors by Total Liabilities
The table below lists competitors of Oruka Therapeutics, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Yapi ve Kredi Bankasi AS
IS:YKBNK
|
Turkey | TL3.27 Trillion |
|
Liquidia Technologies Inc
NASDAQ:LQDA
|
USA | $326.80 Million |
|
Chailease Holding Co Ltd
TW:5871
|
Taiwan | NT$780.63 Billion |
|
Rayonier Inc
NYSE:RYN
|
USA | $1.20 Billion |
|
Loar Holdings Inc.
NYSE:LOAR
|
USA | $1.12 Billion |
|
MGIC Investment Corp
NYSE:MTG
|
USA | $1.51 Billion |
|
Fastighets AB Balder (publ)
ST:BALD-B
|
Sweden | Skr175.89 Billion |
|
Credit Acceptance Corporation
NASDAQ:CACC
|
USA | $7.03 Billion |
Liability Composition Analysis (2005–2025)
This chart breaks down Oruka Therapeutics, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Oruka Therapeutics, Inc. balance sheet independence to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 38.51 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Oruka Therapeutics, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Oruka Therapeutics, Inc. (2005–2025)
The table below shows the annual total liabilities of Oruka Therapeutics, Inc. from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $16.69 Million | +20.94% |
| 2024-12-31 | $13.80 Million | +1540.67% |
| 2023-12-31 | $841.00K | -40.44% |
| 2022-12-31 | $1.41 Million | -63.62% |
| 2021-12-31 | $3.88 Million | -0.69% |
| 2020-12-31 | $3.91 Million | +322.03% |
| 2019-12-31 | $926.00K | +16.77% |
| 2018-12-31 | $793.00K | -62.06% |
| 2017-12-31 | $2.09 Million | -14.17% |
| 2016-12-31 | $2.44 Million | +61.90% |
| 2015-12-31 | $1.50 Million | +8.12% |
| 2014-12-31 | $1.39 Million | -7.45% |
| 2013-12-31 | $1.50 Million | +392.79% |
| 2012-12-31 | $305.00K | -60.39% |
| 2011-12-31 | $770.00K | -44.40% |
| 2010-12-31 | $1.39 Million | -29.34% |
| 2009-12-31 | $1.96 Million | -88.04% |
| 2008-12-31 | $16.39 Million | -69.09% |
| 2007-12-31 | $53.02 Million | -53.72% |
| 2006-12-31 | $114.56 Million | +123.40% |
| 2005-12-31 | $51.28 Million | -- |
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-… Read more